We are live on ! Find out more
XTLB

XTL Biopharmaceuticals
XTLB

5 hedge funds and large institutions have $579K invested in XTL Biopharmaceuticals in 2016 Q4 according to their latest regulatory filings, with 1 funds opening new positions, 2 increasing their positions, 1 reducing their positions, and 1 closing their positions.

New
Increased
Maintained
Reduced
Closed

100% more repeat investments, than reductions

Existing positions increased: 2 | Existing positions reduced: 1

0.01% more ownership

Funds ownership: 3.53% → 3.54% (+0.01%)

0% more funds holding

Funds holding: 5 → 5 (0)

0% more first-time investments, than exits

New positions opened: 1 | Existing positions closed: 1

36% less capital invested

Capital invested by funds: $907K → $579K (-$328K)

Holders
5
Holders Change
–
Holders Change %
0%
% of All Funds
0.12%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
1
Increased
2
Reduced
1
Closed
1
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
UBS Group
UBS Group
Switzerland
+$12.9K
2
Citadel Advisors
Citadel Advisors
Florida
+$9.54K
3
Morgan Stanley
Morgan Stanley
New York
+$607

Top Sellers

Rank Fund Capital Flow
1
SM
Sabby Management
Florida
-$20.6K
2
TRCT
Tower Research Capital (TRC)
New York
-$1K

XTLB Hedge Fund Activity: Q4 2016 in Review

5 of the 4,008 institutional investors tracked by Wall St. Rank reported a position in XTL Biopharmaceuticals (XTLB) for Q4 2016, worth a combined $579K — down 36% from $907K a quarter earlier.

Fund positioning in XTLB was balanced in Q4 2016: 1 fund opened new positions, 1 closed out, 2 added to existing stakes and 1 trimmed.

The largest buyer was UBS Group, opening a new position worth an estimated $12.9K. The largest seller was Sabby Management, cutting an estimated $20.6K.

  • 5 institutional investors held XTL Biopharmaceuticals (XTLB) as of Q4 2016, unchanged from Q3 2016.
  • Funds reported $579K of XTL Biopharmaceuticals stock for Q4 2016, down 36% quarter-over-quarter.
  • 1 fund opened new XTL Biopharmaceuticals positions in Q4 2016 and 1 closed out, a net change of 0 holders.
  • The largest XTL Biopharmaceuticals buyer in Q4 2016 was UBS Group, an estimated $12.9K added.
  • The largest XTL Biopharmaceuticals seller in Q4 2016 was Sabby Management, an estimated $20.6K sold.

Based on aggregated 13F filings for Q4 2016.